Runying Yang
YOU?
Author Swipe
View article: Evidence of fructose metabolism in colorectal cancer
Evidence of fructose metabolism in colorectal cancer Open
View article: Multitask radioclinical decision stratification in non-metastatic colon cancer: integrating MMR status, pT staging, and high-risk pathological factors
Multitask radioclinical decision stratification in non-metastatic colon cancer: integrating MMR status, pT staging, and high-risk pathological factors Open
The multi-task machine learning model proposed in this study enables non-invasive and precise preoperative stratification of patients with NMCC based on MMR status, pT stage, and pathological risk factors. This predictive tool demonstrates…
View article: ERK signaling promotes IKKε expression and oncogenic functions in pancreatic cancer cells in association with TBK1
ERK signaling promotes IKKε expression and oncogenic functions in pancreatic cancer cells in association with TBK1 Open
A variety of cancers utilize RAS-regulated signaling pathways to promote oncogenic phenotypes. A widely studied example is pancreatic cancer, where mutant KRAS signaling leads to activation of MEK (mitogen-activated protein kinase/extracel…
View article: Supplementary Figure S6 from Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer
Supplementary Figure S6 from Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer Open
RAS ERK-MAPK pathway inhibition induces autophagic flux and synergizes with PIKfyvei to impair proliferation of PDAC cell lines
View article: Supplementary Figure S5 from Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer
Supplementary Figure S5 from Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer Open
PIKfyve inhibition results in the formation of LAMP-1 positive vacuoles
View article: Supplementary Figure S7 from Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer
Supplementary Figure S7 from Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer Open
MEK inhibition synergizes with PIKfyvei to impair proliferation of PDAC cell lines
View article: Data from Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer
Data from Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer Open
Pancreatic ductal adenocarcinoma (PDAC) is characterized by KRAS- and autophagy-dependent growth. Inhibition of the KRAS–RAF–MEK–ERK pathway enhances autophagic flux and dependency, and concurrent treatment with the nonspecific auto…
View article: Supplementary Figure S10 from Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer
Supplementary Figure S10 from Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer Open
Complete results of Apoptosis Array
View article: Supplementary Table 2 from Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer
Supplementary Table 2 from Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer Open
RPPA antibody list
View article: Supplementary Figure S9 from Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer
Supplementary Figure S9 from Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer Open
Combined inhibition of PIKfyve and the RAS ERK-MAPK pathway induces apoptosis in PDAC cell lines
View article: Supplementary Figure S4 from Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer
Supplementary Figure S4 from Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer Open
Chemically distinct PIKfyve inhibitors block proliferation and autophagy in PDAC cells
View article: Supplementary Figure S3 from Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer
Supplementary Figure S3 from Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer Open
The PIKfyve inhibitor apilimod impairs autophagic flux in PDAC cells
View article: Supplementary Table 1 from Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer
Supplementary Table 1 from Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer Open
Key research resource identifiers
View article: Supplementary Figure S2 from Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer
Supplementary Figure S2 from Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer Open
The PIKfyve inhibitor apilimod impairs proliferation and blocks autophagy in PDAC cells
View article: Supplementary Figure S11 from Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer
Supplementary Figure S11 from Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer Open
PIKfyve inhibition sensitizes PDAC organoids to RAS ERK-MAPK inhibition
View article: Supplementary Figure S8 from Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer
Supplementary Figure S8 from Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer Open
Combined inhibition of PIKfyve and RAS or MEK durably represses PDAC cell proliferation
View article: Supplementary Figure S1 from Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer
Supplementary Figure S1 from Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer Open
Identification of PIKfyve as a potential anti-autophagy target in PDAC
View article: Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer
Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer Open
To delineate the mechanisms by which the ERK1 and ERK2 mitogen-activated protein kinases support mutant KRAS-driven cancer growth, we determined the ERK-dependent phosphoproteome in KRAS-mutant pancreatic cancer. We determined that ERK1 an…
View article: Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer.
Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer. Open
Mutational loss of CDKN2A (encoding p16INK4A) tumor-suppressor function is a key genetic step that complements activation of KRAS in promoting the development and malignant growth of pancreatic ductal adenocarcinoma (PDAC). However, pharma…
View article: Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy InhibitorsIGF1R Inhibition Enhances Dual ERK and Autophagy Inhibition
Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy InhibitorsIGF1R Inhibition Enhances Dual ERK and Autophagy Inhibition Open
The aggressive nature of pancreatic ductal adenocarcinoma (PDAC) mandates the development of improved therapies. As KRAS mutations are found in 95% of PDAC and are critical for tumor maintenance, one promising strategy involves exploiting …
View article: CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment
CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment Open
View article: Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer
Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer Open
To delineate the mechanisms by which the ERK1 and ERK2 mitogen-activated protein kinases support mutant KRAS–driven cancer growth, we determined the ERK-dependent phosphoproteome in KRAS-mutant pancreatic cancer. We determined that ERK1 an…
View article: Data from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Data from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer Open
Mutational loss of CDKN2A (encoding p16INK4A) tumor-suppressor function is a key genetic step that complements activation of KRAS in promoting the development and malignant growth of pancreatic ductal adenocarcinoma (PDAC). However, pharma…
View article: Figure S2 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Figure S2 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer Open
Figure S2 page2
View article: Figure S4 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Figure S4 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer Open
Figure S4 page1
View article: Supplementary Data and Materials from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Supplementary Data and Materials from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer Open
Supplementary Data and Materials
View article: Supplementary Figure from Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy Inhibitors
Supplementary Figure from Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy Inhibitors Open
Supplementary Figure from Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy Inhibitors
View article: Figure S5 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Figure S5 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer Open
Figure S5 page2
View article: Supplementary Data and Materials from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Supplementary Data and Materials from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer Open
Supplementary Data and Materials
View article: Data from Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy Inhibitors
Data from Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy Inhibitors Open
The aggressive nature of pancreatic ductal adenocarcinoma (PDAC) mandates the development of improved therapies. As KRAS mutations are found in 95% of PDAC and are critical for tumor maintenance, one promising strategy involves expl…